Peter Attia· MD
small prostate unresponsive to medical management persistent symptoms you better be doing urinary cytology in my opinion you need to do a workup to rule that out for sure
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
small prostate unresponsive to medical management persistent symptoms you better be doing urinary cytology in my opinion you need to do a workup to rule that out for sure
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
if you develop if you're developing profound urinary symptoms and you have a small prostate you have to start looking for other sources and and by definition you're not responding to two classes of drugs yes you have to worry about cancers not prostate cancer but you have to worry about urethal carcinoma ureel carcinoma which is a cancer in the aligning of the bladder but also can even get into the urethra
if you develop if you're developing profound urinary symptoms and you have a small prostate you have to start looking for other sources and and by definition you're not responding to two classes of drugs yes you have to worry about cancers not prostate cancer but to worry about urethal carcinoma ureel carcinoma which is a cancer in the lining of the bladder but also can even get into the urethra
small prostate unresponsive to medical management persistent symptoms you better be doing urinary cytology in my opinion you need to do a workup to rule that out for sure
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.